Alnylam Pharmaceuticals Inc (ALNY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alnylam Pharmaceuticals Inc (ALNY) has a cash flow conversion efficiency ratio of 0.207x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($163.56 Million) by net assets ($789.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALNY equity to assets ratio to measure how much of total assets are equity-financed.
Alnylam Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Alnylam Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ALNY cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Alnylam Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alnylam Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deutsche Börse AG
XETRA:DB1
|
0.124x |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
-0.236x |
|
ArcelorMittal SA
MC:MTS
|
0.000x |
|
Advanced Micro Fabrication Inc
SHG:688012
|
0.053x |
|
Take-Two Interactive Software Inc
NASDAQ:TTWO
|
0.067x |
|
CITIC LTD. ADR/5 HD-40
F:CPF0
|
N/A |
|
Commerzbank AG
XETRA:CBK
|
-0.209x |
|
Adani Enterprises Limited
NSE:ADANIENT
|
0.010x |
Annual Cash Flow Conversion Efficiency for Alnylam Pharmaceuticals Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Alnylam Pharmaceuticals Inc from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see Alnylam Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $789.18 Million | $524.08 Million | 0.664x | +636.00% |
| 2024-12-31 | $67.09 Million | $-8.31 Million | -0.124x | +73.75% |
| 2023-12-31 | $-220.64 Million | $104.16 Million | -0.472x | -113.80% |
| 2022-12-31 | $-158.22 Million | $-541.27 Million | 3.421x | +413.58% |
| 2021-12-31 | $588.20 Million | $-641.69 Million | -1.091x | -80.28% |
| 2020-12-31 | $1.02 Billion | $-614.96 Million | -0.605x | -212.68% |
| 2019-12-31 | $1.44 Billion | $-278.43 Million | -0.194x | +55.22% |
| 2018-12-31 | $1.30 Billion | $-562.62 Million | -0.432x | -99.41% |
| 2017-12-31 | $1.77 Billion | $-382.79 Million | -0.217x | +35.19% |
| 2016-12-31 | $920.22 Million | $-307.70 Million | -0.334x | -123.59% |
| 2015-12-31 | $1.26 Billion | $-189.14 Million | -0.150x | +15.47% |
| 2014-12-31 | $936.27 Million | $-165.64 Million | -0.177x | +30.34% |
| 2013-12-31 | $270.35 Million | $-68.66 Million | -0.254x | +70.55% |
| 2012-12-31 | $134.05 Million | $-115.61 Million | -0.862x | -16.88% |
| 2011-12-31 | $118.00 Million | $-87.07 Million | -0.738x | -38.44% |
| 2010-12-31 | $158.23 Million | $-84.34 Million | -0.533x | -31.48% |
| 2009-12-31 | $177.97 Million | $-72.14 Million | -0.405x | -225.12% |
| 2008-12-31 | $202.12 Million | $65.49 Million | 0.324x | -67.16% |
| 2007-12-31 | $199.17 Million | $196.52 Million | 0.987x | +905.92% |
| 2006-12-31 | $201.17 Million | $-24.63 Million | -0.122x | +54.12% |
| 2005-12-31 | $61.78 Million | $-16.48 Million | -0.267x | +37.09% |
| 2004-12-31 | $46.14 Million | $-19.57 Million | -0.424x | -188.30% |
| 2003-12-31 | $-26.71 Million | $-12.83 Million | 0.480x | +74.62% |
| 2002-12-31 | $-4.65 Million | $-1.28 Million | 0.275x | -- |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more